Home  >  News
Msc_Apr22 Advertisement
6Sugar_Free_Sweetener.gif
you can get e-magazine links on WhatsApp. Click here
Clinical Trials + Font Resize -

Hutchmed begins phase I trial of HMPL-653 to treat advanced malignant solid tumours and TGCT

Hong Kong, Shanghai
Friday, January 21, 2022, 12:00 Hrs  [IST]

Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that it has initiated a phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022.

The phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-653 in the treatment of patients with advanced or metastatic solid tumours and tenosynovial giant cell tumours (“TGCT”). Approximately 110 patients are expected to be enrolled in the dose escalation and expansion phase of this study. The primary endpoints are dose limiting toxicity, safety, tolerability, recommended phase II dose and maximum tolerated dose. The secondary endpoints include pharmacokinetics, objective response rate, progression free survival, disease control rate, and overall survival. The lead principal investigator is Dr Cheng Ying of the Jilin Cancer Hospital, which is the lead institution for this study.

HMPL-653 is an investigational novel, highly selective, and potent CSF-1R inhibitor designed to target malignant driven tumours as a monotherapy or in combination with other drugs.

CSF-1R is usually expressed on the surface of macrophages and can promote growth and differentiation of macrophages after binding with its ligand, CSF-1. A number of studies have shown that blocking the CSF-1R signalling pathway could effectively modulate the tumour microenvironment, relieve tumour immunosuppression, and synergize with other anti-cancer therapies such as immune checkpoint inhibitors to achieve tumour inhibition. It has been demonstrated in several clinical studies that other CSF-1R inhibitors, by inhibiting CSF-1R activity, could be used to treat TGCT, and to treat a variety of malignancies through combination with immuno-oncology and/or other therapeutic agents. Currently no CSF-1R inhibitor has been approved in China.

Hutchmed currently retains all rights to HMPL-653 worldwide.

TGCT is a very rare type of soft tissue tumour caused by abnormal proliferation and inflammation of giant cells, monocytes and inflammatory cells. These tumours are mainly characterized by the expression of CSF-1. Targeting CSF-1R has become an effective therapeutic strategy for TGCT. The incidence of TGCT is approximately between 1.8 and 50 per 1 million people. Surgery is the standard treatment for TGCT patients. However, among patients with diffuse or recurrent/refractory TGCT, tumours are wrapped in peripheral organs such as bone, tendon, ligament and joint, which makes removal by surgery difficult. The recurrence rate of diffuse-type cases is estimated to be 21% to 50%. There is a high unmet need for effective and safe treatment for these patients.

Hutchmed is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |